Compare FuelCell Energy Inc (FCEL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Mesoblast Limited — how do they compare? FuelCell Energy Inc trades at $17.32 (market cap $1.62B), while Mesoblast Limited trades at $18.77 (market cap $2.31B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | MESO | |
|---|---|---|
Market Cap | $1.62B | $2.31B |
Sector | Industrials | Technology |
52-Week High | $36.01 | $20.96 |
52-Week Low | $3.92 | $11.35 |
Enterprise Value | $1.47B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.35, down 18.74% over 24 hours, reflecting recent volatility. The stock shows a bearish technical signal with support at $17 and resistance at $21. Fundamentally, the company reported a net loss of $187.90 million on $158.16 million revenue in 2025, with negative profit margins persisting. Recent news highlights a partnership with Siemens for scalable fuel cell solutions and a $225 million stock offering that caused dilution concerns. Analyst consensus is mixed with a $20.75 price target.
FCEL presents high-risk growth potential driven by AI data center energy demand and strategic partnerships, but faces significant challenges including consistent losses, cash burn, and shareholder dilution. The stock's outlook hinges on execution of commercial projects and path to profitability, with substantial downside risk if growth catalysts fail to materialize.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
